We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+7.21%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$166M
AUM Growth
+$16.8M
(+11%)
Cap. Flow
+$19.2M
Cap. Flow
% of AUM
11.58%
Top 10 Holdings %
Top 10 Hldgs %
22.19%
Holding
254
New
38
Increased
43
Reduced
118
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$3.61M |
| 2 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
+$3.1M |
| 3 |
Axsome Therapeutics
AXSM
|
+$2.73M |
| 4 |
Pfizer
PFE
|
+$2.64M |
| 5 |
TRML
Tourmaline Bio
TRML
|
+$2.15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$3.78M |
| 2 |
WBA
Walgreens Boots Alliance
WBA
|
+$3.13M |
| 3 |
ABVX
Abivax
ABVX
|
+$2.86M |
| 4 |
Ironwood Pharmaceuticals
IRWD
|
+$2.8M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$2.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.45% |
| 2 | Real Estate | 11.2% |
| 3 | Financials | 4.6% |
| 4 | Industrials | 3.92% |
| 5 | Technology | 2.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Pfizer
PFE
$143B
| $4.86M | 2.93% |
175,000
+95,000
| +119% | +$2.64M |
|
2
Rithm Capital
RITM
$5.2B
| $4.7M | 2.83% |
420,966
+20,000
| +5% | +$215K |
|
3
Harmony Biosciences
HRMY
$1.96B
| $4.1M | 2.47% |
122,000
| – | – |
|
|
4
United Therapeutics
UTHR
$22.7B
| $3.68M | 2.22% |
+16,000
| New | +$3.61M |
|
5
Pacira BioSciences
PCRX
$1.01B
| $3.43M | 2.07% |
117,500
| – | – |
|
6
BioCryst Pharmaceuticals
BCRX
$2.36B
| $3.43M | 2.07% |
675,000
| – | – |
|
|
LKFT
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
| $3.38M | 2.04% |
105,000
| – | – |
|
8
argenx
ARGX
$53.8B
| $3.15M | 1.9% |
8,000
+250
| +3% | +$96.9K |
|
|
NARI
9
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $3.02M | 1.82% |
63,000
+58,000
| +1,160% | +$3.1M |
|
10
DocGo
DCGO
$64.3M
| $2.63M | 1.58% |
650,000
+340,000
| +110% | +$1.28M |
|
|
ONC
11
BeOne Medicines Ltd
ONC
$32.4B
| $2.62M | 1.58% |
16,750
+9,250
| +123% | +$1.49M |
|
|
EFC
12
Ellington Financial
EFC
$1.7B
| $2.62M | 1.58% |
221,602
| – | – |
|
|
13
Axsome Therapeutics
AXSM
$11.8B
| $2.59M | 1.56% |
+32,500
| New | +$2.73M |
|
14
MGIC Investment
MTG
$6.23B
| $2.56M | 1.54% |
114,379
+35,000
| +44% | +$698K |
|
15
uniQure
QURE
$2.77B
| $2.39M | 1.44% |
460,000
+38,975
| +9% | +$224K |
|
16
Coherus Oncology
CHRS
$216M
| $2.39M | 1.44% |
1,000,000
| – | – |
|
17
Mirum Pharmaceuticals
MIRM
$7.25B
| $2.36M | 1.42% |
94,000
+44,000
| +88% | +$1.21M |
|
|
DX
18
Dynex Capital
DX
$2.87B
| $2.26M | 1.36% |
181,492
| – | – |
|
19
UroGen Pharma
URGN
$1.96B
| $2.16M | 1.3% |
143,898
-11,102
| -7% | -$181K |
|
20
Corcept Therapeutics
CORT
$9.72B
| $2.14M | 1.29% |
+85,000
| New | +$2.01M |
|
21
Perspective Therapeutics
CATX
$341M
| $2.09M | 1.26% |
+175,676
| New | +$1.5M |
|
|
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
| $2.06M | 1.24% |
175,000
+35,000
| +25% | +$448K |
|
|
EXAS
23
DELISTED
Exact Sciences
EXAS
| $2M | 1.21% |
+29,000
| New | +$1.83M |
|
|
MFA
24
MFA Financial
MFA
$960M
| $1.91M | 1.15% |
167,725
+25,000
| +18% | +$280K |
|
|
RWT
25
Redwood Trust
RWT
$641M
| $1.84M | 1.11% |
288,343
+141,750
| +97% | +$926K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q1 2024 Portfolio in Review
As of Q1 2024, AlphaCentric Advisors held 254 positions worth $166M, up 11% from $149M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
AlphaCentric Advisors deployed $19.2M of net new capital in Q1 2024, opening 38 new positions and adding to 43 existing holdings. Its largest new stake was United Therapeutics: 16,000 shares worth $3.68M.
By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 59% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was Invesco NASDAQ 100 ETF, an estimated $1.72M trimmed.
- AlphaCentric Advisors's largest Q1 2024 buy was United Therapeutics: 16,000 shares worth $3.68M.
- AlphaCentric Advisors added most to Inari Medical, Inc. Common Stock in Q1 2024, an estimated $3.1M increase.
- AlphaCentric Advisors's biggest Q1 2024 reduction was Invesco NASDAQ 100 ETF, cutting an estimated $1.72M.
- AlphaCentric Advisors fully exited Immunogen Inc in Q1 2024, selling an estimated $3.78M.
- AlphaCentric Advisors's ten largest holdings make up 22% of its $166M portfolio in Q1 2024.
- AlphaCentric Advisors opened 38 new positions and closed 26 in Q1 2024.
- AlphaCentric Advisors's portfolio value rose 11% quarter-over-quarter to $166M.
Based on AlphaCentric Advisors's 13F filing for Q1 2024, filed 24 Apr 2024.